ClinVar Miner

Submissions for variant NM_022489.4(INF2):c.383T>C (p.Leu128Pro)

dbSNP: rs387907037
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000235466 SCV000293539 likely pathogenic not provided 2017-05-12 criteria provided, single submitter clinical testing The L128P variant has been previously reported in association with CMT and focal segmental glomerulosclerosis (Rodriguez et al., 2013; Boyer et al., 2011). It was not observed in approximately 6,100 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The L128P variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution alters a conserved position in the DID domain, where other pathogenic variants associated with CMT-FSGS have been reported (Stenson et al., 2014). In silico analysis predicts this variant is probably damaging to the protein structure/function. Therefore, this is a strong candidate for a pathogenic variant, however the possibility that it is a benign variant cannot be excluded.
Invitae RCV001378421 SCV001575985 pathogenic Focal segmental glomerulosclerosis 5; Charcot-Marie-Tooth disease dominant intermediate E 2024-01-08 criteria provided, single submitter clinical testing This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 128 of the INF2 protein (p.Leu128Pro). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with Charcot-Marie-Tooth disease and focal segmental glomerulosclerosis (PMID: 22187985, 22961558). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 30867). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt INF2 protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV002362594 SCV002626032 pathogenic Inborn genetic diseases 2020-06-17 criteria provided, single submitter clinical testing The p.L128P variant (also known as c.383T>C), located in coding exon 1 of the INF2 gene, results from a T to C substitution at nucleotide position 383. The leucine at codon 128 is replaced by proline, an amino acid with similar properties. This alteration is located in the diaphanous inhibitory domain (DID), where pathogenic alterations are localized between nucleotide positions 300 to 500 in patients with both Charcot-Marie-Tooth disease, intermediate E (CMTDIE) and focal segmental glomerulosclerosis 5 (FSGS) (Boyer O et al. N. Engl. J. Med., 2011 Dec;365:2377-88). This variant has been found in multiple individuals with CMT and FSGS and was reported as de novo in one individual (Boyer O et al. N. Engl. J. Med., 2011 Dec;365:2377-88; Rodriguez PQ et al. Pediatr. Nephrol., 2013 Feb;28:339-43). The variant has also been reported in one individual with an unspecified inherited neuropathy phenotype (Laššuthová P et al. Orphanet J Rare Dis, 2016 08;11:118). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
OMIM RCV000023852 SCV000045143 pathogenic Charcot-Marie-Tooth disease dominant intermediate E 2011-12-22 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.